Afuco™ Anti-Human HCV ADCC Recombinant Antibody (MBL-HCV1), ADCC Enhanced (CAT#: AFC-329CL)
Anti-HCV ADCC Enhanced Antibody (MBL-HCV1) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) delays HCV viral rebound following liver transplantation. As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.
Specific Inquiry
Figure 1 Changes in viral loads and epitope sequence distributions upon MBL-HCV1 antibody administration.
A–F: Epitope distributions for subjects A, B, C, D, E and F respectively. X axis represents time point in days, 0 denoting pre-transplant baseline sample. Note the depletion of wild-type sequence in all patients and the emergence of resistant epitope sequences (see proportions in left Y axis), in conjunction with viral rebound (right Y axis). Positions 415 and 417 are highlighted in blue in the legend. G: Summary of antibody-resistant mutations in epitope sequences, assuming maximum parsimony. Glycosylation motifs are highlighted in orange.
Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., ... & Florman, S. (2013). Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.American Journal of Transplantation, 13(4), 1047-1054.
Figure 2 Positions in E1/E2 sequence that show the most significant changes in response to antibody treatment.
Left: Median-shifted chi-square statistic values of the top 15 amino acid positions across E1 and E2 that show the most difference in average chi-square statistic between MBL-HCV1- and placebo-treated subjects. Placebo subject J was unable to be analyzed due to post-rebound viral titers <10,000 IU/ml. The chi-square statistic quantifies changes in amino acid distributions between day 0 and day of rebound for each subject in each position across the genome. A higher statistic represents a larger change in the amino acid distribution (darker red in heatmap). Positions labeled in green are those within the MBL-HCV1 epitope. Positions labeled in blue are known to participate in CD81 binding. Positions in pink belong to the E1 sequence. Right: Differences in mean chi-square statistic between MBL-HCV1-treated and placebo patients. Note that change in position 415 is most significant being 10-fold higher than the second-ranked position 417.
Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., ... & Florman, S. (2013). Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.American Journal of Transplantation, 13(4), 1047-1054.
Figure 3 Median change in HCV RNA from baseline during the 56 day study period.
Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., ... & Florman, S. (2013). Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.American Journal of Transplantation, 13(4), 1047-1054.
Figure 4 Mean antibody concentrations to MBL-HCV1 epitope measured during the first week post LT (A) and during the 56 day study period (B) in antibody-treated subjects. Error bars represent standard deviation.
Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., ... & Florman, S. (2013). Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.American Journal of Transplantation, 13(4), 1047-1054.
Specifications
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Related Disease
- Hepatitis C viral infection
Product Property
- Purity
- Purity>95% by SDS-PAGE
- Storage
- 4°C or -20°C, avoid repeated freezing and thawing.
Target
- Alternative Names
- HCV; Hepatitis C virus; HVC
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "HCV"
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-444-S(P) | Recombinant Anti-HCV Antibody scFv Fragment | WB, IHC, FuncS | scFv |
| HPAB-1118LY-S(P) | Humanized Anti-HCV Antibody scFv Fragment (CBL021) | ELISA, FC | |
| HPAB-1119LY-S(P) | Humanized Anti-HCV Antibody scFv Fragment (CBL022) | ELISA, FC | |
| HPAB-1120LY-S(P) | Humanized Anti-HCV Antibody scFv Fragment (CBL023) | ELISA, FC | |
| HPAB-0043LY-S(P) | Mouse Anti-HCV Antibody scFv Fragment (PA-29) | WB | scFv |
Single-domain Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABG-079 | Recombinant Anti-HCV VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MHH-444 | Recombinant Human Anti-HCV Antibody | IF, Neut, FuncS | IgG |
| HPAB-0043LY | Recombinant Mouse Anti-HCV Antibody (PA-29) | WB | |
| FAMAB-0024WJ | Human Anti-HCV Recombinant Antibody (clone B12.F8) | ELISA, IF, IHC, WB | Human IgG |
| FAMAB-0025WJ | Human Anti-HCV Recombinant Antibody (clone CM3.B6) | ELISA, IF, IHC, WB, Inhib | Human IgG |
| FAMAB-0026WJ | Human Anti-HCV Recombinant Antibody (clone E6.D10) | ELISA, IF, IHC | Human IgG |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-344CL | Human Anti-HCV Recombinant Antibody (TAB-344CL) | FuncS | Human IgG |
| PABX-071 | Recombinant Human Anti-HCV Antibody (HC33.4) | WB, ELISA, Neut, FuncS | IgG |
| PABX-079 | Recombinant Human Anti-Hepatitis C virus Antibody (AP33) | WB, ELISA, FuncS | IgG |
| PABX-071-F (E) | Recombinant Human Anti-HCV Antibody Fab Fragment (HC33.4) | WB, ELISA, Neut, FuncS | Fab |
| PABX-079-F (E) | Recombinant Human Anti-Hepatitis C virus Antibody Fab Fragment (AP33) | WB, ELISA, FuncS | Fab |
Mouse Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABX-071-S (P) | Recombinant Human Anti-HCV Antibody scFv Fragment (HC33.4) | WB, ELISA, Neut, FuncS | scFv |
| PABX-079-S (P) | Recombinant Human Anti-Hepatitis C virus Antibody scFv Fragment (AP33) | WB, ELISA, FuncS | scFv |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-1118LY-F(E) | Humanized Anti-HCV Antibody Fab Fragment (CBL021) | ELISA, FC | |
| HPAB-1119LY-F(E) | Humanized Anti-HCV Antibody Fab Fragment (CBL022) | ELISA, FC | |
| HPAB-1120LY-F(E) | Humanized Anti-HCV Antibody Fab Fragment (CBL023) | ELISA, FC | |
| HPAB-1121LY-F(E) | Humanized Anti-HCV Antibody Fab Fragment (CBL024) | ELISA, FC | |
| HPAB-0232-FY-F(E) | Recombinant Human Anti-HCV Antibody Fab Fragment (TRN1007) | WB, F, N | Human Fab |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-329CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.